ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915

Also written as “JNJ-101556143” and “JNJ-101556143 Formulation 1”.

Its studies are mostly in Prostatic Neoplasms, led by Johnson & Johnson.

Drug pageAndrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 26, 20263 company-led studies, 3 open or runningNext primary completion: Feb 14, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson33 open or runningphase 3since Oct 26, 2026Jan 20, 2025Feb 14, 2028phase 3 · NCT07906717
  • Named in Johnson & Johnson’s own pipeline as JNJ-6143 (HLD-0915), phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06800313 · 190 planned · United States, United Kingdom
  2. Sep 16, 2026Phase 2 study in Prostatic NeoplasmsNCT07832292 · 100 planned · United States, Australia, China and more
  3. Oct 26, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedNCT07906717 · 400 planned · United States, Israel

Ahead

  1. Feb 14, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07906717
  2. Aug 17, 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT06800313
  3. May 17, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07832292

TargetBeta

“An orally bioavailable bifunctional small molecule composed of an androgen receptor (AR)-binding moiety that is conjugated, via a linker, to a bromodomain-containing protein 4 (BRD4)-binding moiety, with potential antineoplastic activity. Upon oral administration of AR-targeting regulated induced…”NCIt, read by Claude
“An orally bioavailable bifunctional small molecule composed of an androgen receptor (AR)-binding moiety that is ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07906717Prostatic Neoplasms · United States, Israel3RecruitingFeb 14, 2028400
NCT07832292Prostatic Neoplasms · United States, Australia, China and more2RecruitingMay 17, 2029100
NCT06800313Prostatic Neoplasms · United States, United Kingdom2RecruitingAug 17, 2028190

How it is read

Names in the registry

  • “JNJ-101556143”, 2 entries
  • “JNJ-101556143 Formulation 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.